Biotech

All Articles

Despite combined market, a venture capital revival might be being available in Europe: PitchBook

.While the biotech assets scene in Europe has actually slowed rather adhering to a COVID-19 backing ...

8 months after a $213M fundraise, gene publisher Tome helps make cuts

.After increasing $213 million in 2023-- one of the year's biggest private biotech shots-- Tome Bios...

BioMarin creates exec crew with biotech vets-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our roundup of significant leadership hirings, firings and r...

Biopharma Q2 VC attacked highest degree because '22, while M&ampA slowed

.Financial backing backing into biopharma cheered $9.2 billion across 215 sell the 2nd fourth of the...

Bicara, Zenas seek IPOs to drive late-phase properties towards market

.Bicara Therapeutics and also Zenas Biopharma have delivered new incentive to the IPO market along w...

Genentech to finalize cancer cells immunology research team

.Genentech is going to close its own cancer cells immunology study team, as well as device head and ...

Kezar falls strong cyst yet to prove its own truly worth in phase 1 trial

.Kezar Life Sciences is falling its dim phase 1 strong growth medicine as the biotech goes all-in on...

Acelyrin falls izokibep, lays off 3rd of team

.Despite izokibep preserving its newly found winning touch in the facility, Acelyrin is no longer fo...

Rivus' period 2 obesity-related heart failure test attacks endpoint

.Rivus Pharmaceuticals has plumped up the customers of its own fat-busting, muscle-sparing medicine ...

Ovid halts preclinical work, IV program after soticlestat fall short

.Ovid Therapy already exposed last month that it was actually trimming back its own headcount as the...